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Abstract 
Objectives 
The therapeutic scheme for non-small cell lung cancer (NSCLC) patients can be 
improved if adapted to the individual response. For example, 60-70% of 
adenocarcinoma patients show response to EGFR-tyrosine kinase inhibitors in the 
presence of mutated EGFR. We searched for additional target molecules involved in 
the action of the EGFR-tyrosine kinase inhibitor erlotinib in the absence of EGFR 
mutations, which might be suitable for combinatorial therapy approaches. 
 
Materials and Methods 
Erlotinib-response associated proteins were investigated in patient-derived NSCLC 
mouse xenografts by reverse-phase protein array technology (RPPA) and Western 
blotting. A combinatorial treatment approach was carried out in NSCLC cell lines and 
H1299 mouse xenografts, and subsequently analysed for consequences in cell 
growth and signal transduction. 
 
Results 
AMP-activated protein kinase (AMPK) expression was increased in erlotinib 
responders before and after treatment. In a combinatorial approach, activation of 
AMPK by A-769662 and erlotinib treatment showed a synergistic effect in cell growth 
reduction and apoptosis activation in H1299 cells compared to the single drugs. 
 AMPK pathway analyses revealed an effective inhibition of mTOR signaling by drug 
combination. In H1299 xenografts, the tumor size was significantly decreased after 
combinatorial treatment.  
 
 
Conclusion 
Our results suggest that AMPK activation status affects can be useful to enhance 
response to erlotinib in distinct lung tumor models. 
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1. Introduction 
Recent efforts in lung cancer research to detect driver mutations and novel target 
sites hold promise to categorize lung cancer patients for suitable therapy regimens. 
For example, the EGFR-TKI erlotinib represents a potentially effective cancer drug 
for a subset of lung tumors dependent on the mutation status of EGFR and KRAS 
(Eberhard et al., 2005; Miller et al., 2008; Zhou et al., 2011). However, 30-40% of 
patients do not respond to therapy, and most of the Erlotinib responders develop 
resistance after few months (Ettinger et al., 2012). In the absence of EGFR 
mutations, 1-8% of patients respond (Mok, NEJM, 2009; Jaenne, JCO, 2012; 
Garassino, Lancet, 2013). A better stratification of patients for EGFR-TKI is 
hampered by the fact that drug sensitivity depends on the mutation type of the target 
and subsequently on the activation status of EGFR downstream pathway and 
potential bypass signaling (Martini et al., 2012). Thus, additional predictive 
biomarkers are needed to improve patient stratification, and to suggest novel targets 
for mono- or combination therapy.  
AMP-activated protein kinase (AMPK) activators and inhibitors are under 
investigation as novel cancer drugs (Liang and Mills, 2013). However, the different 
functions of AMPK signaling suggest an ambivalent role in oncogenic transformation. 
In general, AMPK is activated by cellular stress like starvation and regulates energy 
homeostasis (Faubert et al., 2013; Kato et al., 2002). Furthermore, AMPK is an 
upstream regulator of mTOR signaling proposing a tumor suppressor role (Gwinn et 
al., 2008). 
In the present study, tumor specimens from twenty-five individual patient-derived lung 
cancer xenograft models before and after treatment were analyzed. Their drug 
sensitivity to chemotherapeutics and EGFR inhibitors has been characterized 
 (Fichtner et al., 2008). These NSCLC xenografts, predominantly EGFR wildtype, 
were screened for putative biomarkers and novel drug targets associated with 
therapy response to EGFR-TKIs. The drug response patterns and protein profiles 
before and after treatment of NSCLC models suggested AMPK as putative target 
protein. Combinatorial treatment including AMPK activators in diverse lung cancer 
cell lines and a H1299 xenograft model was done to investigate changes in erlotinib 
sensitivity and tumor growth. Furthermore, the consequences on signal transduction 
pathways upon single and combinatorial treatment were examined on the protein 
level. 
 
2. Materials and methods 
2.1 NSCLC xenograft models 
Animals were handled according to regulations established by the European 
Community Council Directive and to protocols approved by the animal care and use 
committee of the State Office of Health and Social Affairs Berlin (LAGeSo; permit 
04520). Details about drug response data, mutation status and NSCLC histology of 
individual tumors have been previously reported (Fichtner et al., 2008). The models 
don't harbor activating EGFR mutations.  
Xenografts of the NSCLC cell line H1299 were established by subcutaneous 
implantation of 1x107 cells to female NMRI:nu/nu mice (6-8 weeks old). At palpable 
tumor size (75-100mm³) five mice each were randomly distributed to three treatment 
and one control group. Treatment was initiated at day 7 following the scheme: A-
769662 (Selleck Chemicals Co., Ltd., Houston, USA), 30mg/kg, QD5, i.p. or erlotinib 
(Hoffmann-LaRoche, Grenzach-Wyhlen, Germany), 50mg/kg, QD5, p.o. as 
 monotherapy and in combination therapy. Tumor size was measured in two 
dimensions twice weekly for 34 days. 
 
2.2 Reverse Phase Protein Arrays (RPPA) 
Xenograft tissues (cell lines) were lysed in T-PER (M-PER) buffer (Thermo Fisher 
Scientific, Waltham, USA) including 2 µM staurosporine, 1x PhosStop phosphatase 
and 1x Mini Complete EDTA-free protease inhibitor cocktails (Roche, Mannheim, 
Germany). Proteins were quantified and RPPA spotting was carried out as previously 
described (Loebke et al., 2007). After blocking, slides were incubated for 2 hours at 
RT with primary antibodies (Supplementary Table S1). Antibody-mediated signal 
amplification (AMSA) was used for signal detection (Brase et al., 2010). The average 
intensity of each spot was determined using GenePix Pro 5.0 software (Molecular 
Devices, Ismaning, Germany). Data normalization was done using total protein 
intensity determined by Fast green FCF staining. Data were quality checked relying 
on protein lysate dilution curve data and protein signal intensities. Spearman’s rank 
correlation and correlation test statistics was used to compare protein expression 
with the drug response patterns of the xenografts (T/C values). Proteins were ranked 
according to the p-value without adjustment (p< 0.05). 
 
2.3 Western blotting 
20 µg protein was separated by 6 to 12 % SDS-PAGE gels and blotted to PVDF 
membranes using the Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad, Hercules, CA, 
USA). After blocking, the blots were incubated with primary antibodies 
(Supplementary Table S1) overnight at 4°C. Conjugated secondary goat anti-mouse 
(anti-rabbit) IgG DyLightTM680 (800) antibodies were incubated for 2 hours. Signals 
were detected using the Odyssey® Infrared Imaging System (LI-COR Biosciences).  
  
2.4 Cell culture and drug treatment 
The human NSCLC cell lines H1299, A549 and H1650 were purchased from ATCC 
(Manassas, VA). The cell lines were authenticated and single mutations were 
confirmed in A549 (KRAS, G12S), H1299 (NRAS, Q61K), and H1650 (EGFR, E746 
A750del) using MassARRAY technology (OncoCarta v1.0 Genotyping, Sequenom, 
San Diego, CA; Supplementary Table S4). H1299 and H1650 cells were cultured in 
RPMI-1640 medium, A549 cells in Ham's F-12K medium, with 10% FBS (Life 
Technologies, Carlsbad, CA). The cells were seeded on 96-well plates (6-well plates) 
at densities between 1 and 2x103 (0.5 and 2×105) cells per well. Cells were treated 
with erlotinib (Tarceva, Roche), A-769662 (Selleck Chemicals Co., Ltd., Houston, 
USA), metformin (Enzo Life Sciences, Farmingdale, USA) and AICAR (Cayman 
Chemical Company, USA) at different concentrations. 
 
2.5 Cell viability (WST-1 assay, cell counting) 
Cell viability was analyzed using the “Cell Proliferation Reagent” (WST-1, Roche). 
Absorbance was measured using a microplate reader (Infinite M200, TECAN, 
Männedorf, Switzerland). All treatments were carried out in two independent 
experiments, each with six technical replicates. Cells were counted using an 
improved Neubauer hemocytometer.  
 
2.6 FACS analysis (FACS-PI) 
Cells were harvested by Accutase (Life Technologies) treatment, washed with PBS, 
fixed in 71% ethanol for at least 24 hours at -20°C, treated with RNase A and stained 
with propidium iodide. DNA fragmentation was determined using FACS-PI (Propidium 
iodide). The subG1 DNA content was measured to define apoptotic cells. 
 Cytofluorometric analyses were performed using the BD FACSCanto™ II flow 
cytometer with BD FACSDiva™ software v. 6.1.3 (Becton Dickinson, Heidelberg, 
Germany). FACS analyses were carried out in two independent experiments, each 
with two technical replicates, 72 and 120 hours after treatment. 
 
3. Results 
3.1 Identification of proteins associated with erlotinib therapy response  
Reverse-phase protein analyses were conducted from tumor protein lysates of 25 
untreated xenografts. Raw data from four samples were excluded from further 
analysis for quality reasons. Normalized RPPA data are summarized in 
Supplementary Table S2. Spearman’s correlation between normalized protein 
expression values and erlotinib (or cetuximab) response indicated a potential 
association for 16 out of 77 analyzed proteins in this dataset (Table 1). Higher 
expression of phosphorylated (Thr172) AMP-activated protein kinase (AMPK) alpha 
correlated with a better response to erlotinib (rs= -0.63) and cetuximab (rs= -0.55) 
(Supplementary Figure S1). The expression of AMPK and P-AMPK was further 
investigated by Western blotting in eight xenograft tumors with and without erlotinib-
treatment (Figure 1). In the three best responders (T/C value 26-31), the expression 
of AMPK and P-AMPK was increased after erlotinib treatment, which was not obvious 
in erlotinib non-responders (T/C value 76-97). Weak expression of the proteins was 
shown for two non-responders (7747, 7433). One non-responder (7187) had equal 
target protein expression with and without erlotinib exposure. In one model (7166) 
AMPK expression strongly decreased upon erlotinib treatment indicating a change in 
the signaling cascade of this non-responder. 
 
 3.2 A-769662 treatment activates AMPK in H1299 cells in a dose-dependent 
manner 
Three NSCLC cell lines were treated with different concentrations of A-769662, a 
known activator of AMPK signaling. First, protein expression changes were screened 
by RPPA analysis. In H1299 cells, RPPA data indicated a P-AMPK and PRKCA 
increase upon A-769662 treatment. In A549 cells, Caveolin-1 and P-Acetyl-CoA 
(ACC) showed a higher abundance. In H1650 cells, E2F2 was increased, and P-RB 
and P-S6 were decreased upon A-769662 treatment (Supplementary Table S3). For 
P-AMPK, lowest endogenous protein levels were observed in H1299 cells based on 
RPPA and Western blotting (Figure 2). Increased P-AMPK protein levels dependent 
on elevated A-769662 concentrations were detectable in H1299 cells. H1650 cells 
showed a non-linear P-AMPK increase after A-769662 treatment, A549 cells did not 
show any changes.  
 
3.3 Combinatorial erlotinib and A-769662 treatment decreases cell viability and 
activates apoptosis in H1299 cells  
The sensitivity of three NSCLC cell lines was determined for A-769662 and erlotinib. 
For A-769662, drug sensitivity (IC50: 150-400 µM) decreased from H1299, H1650 to 
A549 cell line (Figure 3 A). For erlotinib, drug sensitivity was highest in H1650 cells 
compared to A549 and H1299, as previously reported (Yauch et al., 2005). 
Combinatorial treatment was most effective in H1299 (50-65% cell viability 
reduction), marginally effective in A549 (10-25%), and not beneficial in H1650 cells 
(Figure 3 B). Cell counting in the same experimental setting confirmed the viability 
decrease in H1299 and A549 cells after combinatorial treatment (Supplementary 
Figure S2). 
 H1299 cells were treated with 5, 7.5 or 10 µM erlotinib alone or in combination with 
15, 45 or 75 µM A-769662. Cell viability was constantly decreased in H1299 cells 
after combined A-769662 and erlotinib treatment (72 hours) in comparison with single 
drugs and DMSO controls (Figure 3 C). A-769662 alone had a marginal effect on cell 
viability (0-10%), erlotinib alone slightly decreased cell viability (7-28%) compared 
with DMSO control (100%). In contrast, combinatorial treatment using A-769662 and 
erlotinib strongly inhibited cell viability (52-76%), with the strongest inhibitory effect at 
the highest concentrations (75 µM A-769662 and 10 µM erlotinib). H1299 cell growth 
between 0 to 72 hours supported the additive combinatorial effects of the A-769662 
and erlotinib combination (Supplementary Figure S3).  
SubG1 FACS detection (PI-staining) of H1299 cells upon 72h and 120h 
combinatorial treatment (10 µM erlotinib, 75 µM A-769662) was carried out. We 
detected the strongest increase of apoptotic (subG1) cells in cultures treated with 
both drugs (21%) in comparison to single drugs (4-7%) and DMSO solvent control 
(3%) (Figure 3 D). This indicated that combinatorial treatment with erlotinib and A-
769662 activates apoptosis in H1299 cells.  
To further corroborate the combinatorial effect, treatment was performed in H1299 
cells with 10 µM erlotinib and the AMPK activators metformin (1 mM) or AICAR (50 
µM). AMPK activation by these compounds also had a positive effect on erlotinib 
sensitivity in H1299 cells: we observed residual cell viability of 56% for metformin and 
of 71% for AICAR (Supplementary Figure S4). 
 
3.4 Combinatorial A-769662 and erlotinib treatment of H1299 cells inhibits 
mTOR signaling  
To identify the molecular consequences of AMPK activation and erlotinib treatment 
on cellular signaling, Western blot analysis of H1299 cells protein lysates after single 
 and combinatorial treatment was carried out (Figure 4). P-AMPK levels differed in 
particular treatment settings between both time points. After 24 hours, AMPK, P-
AMPK and downstream P-ACC levels increased after combinatorial treatment 
indicating activated AMPK signaling. P-mTOR did not differ between single and 
combinatorial treatment. In contrast, P-Raptor, whose phosphorylation inhibits the 
mTOR complex 1 (mTORC1), increased in the presence of AMPK activator A-
769662. The strongest differences were detected for the mTOR downstream proteins 
P-P70S6K and P-S6: their levels strongly decreased in the cells treated with both 
compounds only (6 and 24 hours). Inhibition of P-EIF4B, a downstream protein of 
P70S6K, was most evident after combinatorial treatment (24 hours). The levels of the 
anti-apoptotic protein BCL-xL decreased in the presence of A-769662 (24 hours), 
which might explain the observed induction of apoptosis in H1299 cells in the 
combinatorial treatment. Autophagic cell death was investigated by the conversion of 
LC3-I into LC3-II protein fraction. In our model, A-769662 alone did not induce LC3 
conversion (Supplemental Figure S5). LC3-II fraction and autophagy was induced 
upon erlotinib treatment (48 and 72 hours). This effect was reversible upon 
combinatorial treatment. In summary, the combinatorial treatment had a strong 
inhibitory impact on mTOR downstream signaling compared to AMPK activation or 
erlotinib treatment alone.  
 
3.5 Combinatorial treatment decreases tumor growth in a H1299 mouse 
xenograft model 
The growth inhibitory effects of AMPK activation and erlotinib combinatorial treatment 
were further explored in vivo using human H1299 NSCLC xenografts in mice. The 
mice were treated for 5 days (day 7-11) either with a single drug (erlotinib or A-
769662), in combination or with saline control. Subcutaneous tumor growth (five mice 
 per condition) was measured in vivo for 34 days. Finally, the tumors were surgically 
removed. The combination of erlotinib and A-769662 decreased tumor size 
significantly in comparison to control and single treatment (p=0.03; Figure 5 A). 
Resected tumors (three replicates closest to median size) from different treatment 
regimens are shown to demonstrate growth response. The combination therapy had 
the strongest impact on tumor growth in H1299 xenografts. No significant differences 
in tumor size were observed for the other experimental conditions (Figure 5 B). 
These findings suggested that AMPK activation enhances the antitumor action of 
erlotinib in vivo.  
 
4. Discussion 
EGFR mutations and the EML4-ALK gene fusion represent two molecular alterations 
in about 15% of lung adenocarcinoma patients in Western countries, and affect target 
sites for which drugs are in clinical use (Pao and Chmielecki, 2010). The benefit for 
patients treated with erlotinib and gefitinib was only significant when stratified 
according to EGFR mutation status (Paez et al., 2004; Tsao et al., 2005). However, 
30-40% of patients do not respond to EGFR inhibitors using the current selection 
criteria (Eberhard et al., 2005; Sequist et al., 2008). About 1-8% of patients without 
relevant EGFR mutations are responders (Mok, NEJM, 2009; Jaenne, JCO, 2012; 
Garassino, Lancet, 2013). The complexity of genomic alterations in lung tumors may 
determine these limitations. For example, the role of a KRAS mutation as negative 
predictor for EGFR-targeted therapy is controversially discussed (Roberts et al., 
2010). It is likely that the activity of additional proteins affects the sensitivity against 
EGFR-targeted therapies in individual patients.  
 In this study, NSCLC xenograft models were screened to identify molecules 
associated with therapy response to the EGFR-targeted therapeutics, erlotinib and 
cetuximab. As a novel finding, P-AMPK expression was elevated in several NSCLC 
xenograft models, which subsequently respond better to erlotinib or cetuximab. In 
addition, AMPK and P-AMPK expression was increased after erlotinib treatment in 
the three best responders. These findings suggested that AMPK activation status 
impacts EGFR targeted drug response in distinct lung cancer models. In lung cancer, 
AMPK signaling is connected with important oncogenic pathways, and associated 
with tumorigenesis and progression. It was shown that metformin, a biguanide anti-
diabetic drug and activator of the AMPK signaling, decreases the risk for cancer in 
diabetes patients (Evans et al., 2005). Furthermore, LKB1, a known upstream 
activator of AMPK signaling, has been described as tumor suppressor in lung cancer 
cells and mouse tumors (Ji et al., 2007; Gill et al., 2011).  
In our study, AMPK activation using A-769662 sensitizes lung cancer cells to erlotinib 
treatment. The reduction of cell growth was most convincing in H1299 cells, which 
may due to the low endogenous AMPK levels, its strongest induction via A-769662, 
and insensitivity to erlotinib. AMPK activation using alternative compounds like 
metformin or AICAR confirmed the increased erlotinib sensitivity. Several studies in 
NSCLC and other cancers have shown that response to EGFR-targeted therapeutics 
depends on the activation status of mTOR signaling, and can be increased by 
mTOR-inhibiting agents (Bliesath et al., 2012). An example is a synergistic effect of 
combinatorial treatment with erlotinib and rapamycin (Buck et al., 2006). Moreover, 
upstream AMPK has an impact on mTOR signaling: AMPK can directly 
phosphorylate Raptor, leading to the inhibition of the mTOR complex 1 and cell cycle 
arrest (Gwinn et al., 2008).  
 Solely administration of A-769662 in H1299 raised the protein levels of downstream 
effectors P-ACC and P-Raptor, but did not affect mTOR downstream targets and cell 
growth. In contrast, combination of erlotinib and A-769662 strongly decreased cell 
viability and activated apoptosis in H1299. Apoptosis induction may be due to 
inhibition of the anti-apoptotic protein BCL-xL upon combinatorial treatment. It has 
been described that AMPK is required for BCL-xL mRNA destabilization and initiation 
of intrinsic apoptosis (Day et al., 2011). The observed autophagy-linked LC3 
conversion upon erlotinib has been previously reported (Li YY et al. Lung Cancer 
2013;81:354-361). However, autophagy is likely not the dominant effect on cell 
viability upon combinatorial treatment in our study. In contrast to single treatments, 
combination resulted in a strong reduction of mTOR downstream targets P-P70S6K, 
P-S6 and P-EIF4B, which likely induced cell growth inhibition. These findings might 
be caused by a concerted action of both agents targeting mTOR signaling. In diverse 
tumor entities EGFR mutational status was associated with phosphorylation of mTOR 
and S6 (Dobashi et al., 2011; Fan et al., 2009). In our NSCLC model, inhibition of 
mTOR downstream genes independent of P-mTOR suggests an alternative signal 
transduction mode via phosphorylation of Raptor.  
From three tested NSCLC cell lines, the strongest effects of treatment combination 
were shown in H1299 cells. The impact on tumor growth was confirmed in H1299 
xenograft models. Possibly, specific mutations influence the sensitivity to this 
treatment concept. NRAS mutations were found in about 1% of lung tumors, and cell 
lines like H1299 harboring NRAS mutation behaved insensitive to EGFR-TKI (Ohashi 
et al., 2013). In NRAS-mutant melanoma cells treatment with AMPK activator AICAR 
inhibited cell growth (Petti et al., 2012). In A549 cells, P-AMPK was hardly activated 
by A-769662 that is probably due to a loss of functional LKB1 (Sanchez-Cespedes et 
al., 2002). The detailed crosstalk between EGFR and AMPK signaling concerning 
 dual action on mTOR downstream pathway in the context of specific tumor genome 
alterations has to be further elucidated. 
In conclusion, we observed that AMPK activation using A-769662 sensitizes distinct 
lung cancer cell lines and H1299 xenograft models to erlotinib. The activation status 
of AMPK signaling in a subset of lung tumors may affect the sensitivity to EGFR-
targeted therapies. 
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 Tables 
 
Table 1: Protein expression associated with Erlotinib response (T/C) values in 
xenograft models. Proteins are tested using Spearman correlation and selected by 
p-value < 0.05. 
Erlotinib Response Cetuximab Response 
Protein Detected Phospho-Site Symbol rs p-value rs p-value 
RAF1 none RAF1 -0.6980 0.0004 ns ns 
P-AMPKa Thr172 PRKAA1 -0.6290 0.0022 -0.5500 0.0099 
P-c-Raf S289, S296, S301 RAF1 -0.5970 0.0043 ns ns 
S6K-alpha 1 none RPS6KA1 -0.5590 0.0084 ns ns 
P-cRaf S259 RAF1 -0.5530 0.0093 ns ns 
PDK1 none PDK1 -0.5330 0.0129 ns ns 
TGFB none TGFB1 -0.5200 0.0158 ns ns 
p21 none CDKN1A 0.5160 0.0167 ns ns 
STAT5 none STAT5 -0.5080 0.0187 ns ns 
STAT1 none STAT1 -0.4840 0.0262 ns ns 
RRM1 none RRM1 -0.4750 0.0294 ns ns 
STK4 none STK4 -0.4750 0.0294 ns ns 
STAT3  none STAT3  -0.4570 0.0371 ns ns 
P70S6K1 none RPS6KB1 -0.4510 0.0400 ns ns 
P-mTOR Ser2448 MTOR ns ns -0.4840 0.0262 
ERBB4 none ERBB4 ns ns -0.4510 0.0400 
Legend: Protein expression was compared with tumor response pattern (T/C value) by using 
Spearman's correlation (rs) and linear test. Proteins are ranked according to the p-value (erlotinib). 
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Figure 1: Western blot analysis of Erlotinib-treated and control xenograft 
models. Xenograft models are characterized by erlotinib response pattern 
(Responder top, Non-Responder bottom) based on T/C values. All eight xenograft 
models were treated with erlotinib and normal saline (control). The abundance of the 
proteins AMPK and P-AMPK was determined; ß-Actin staining was used as loading 
control. 
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Figure 2: AMPK activation was determined after A-769662 treatment in lung 
cancer cell lines. Three different lung cancer cell lines were treated with AMPK 
activator A-769662 (0, 10, 50 and 100µM). Proteins were measured by RPPA (P-
AMPK) and western blotting (P-AMPK and ß-Actin loading control).  
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Figure 3: Combinatorial treatment using AMPK activator A-769662 and erlotinib 
inhibits cell growth in diverse NSCLC cell lines and activates apoptosis in 
H1299 cells. (A) Cell viability changes upon treatment with increasing A-769662 
concentrations (72 hours) in different NSCLC cell lines. (B) Cell growth inhibition after 
combinatorial erlotinib (10µM) and A-769662 (15-75µM) treatment compared to 
erlotinib alone. (C) Decreased cell viability was observed in H1299 after combined A-
769662 and erlotinib treatment (72 hours) in diverse concentrations compared to 
single drugs. (D) Induction of apoptosis in H1299 after 72h and 120h combinatorial 
treatment (10µM erlotinib, 75µM A-769662) was detected by SubG1 FACS detection 
(PI-staining).  
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Figure 4: Combinatorial treatment of H1299 cells with A-769662 and erlotinib 
strongly inhibited signaling proteins like p70s6K and S6. Proteins associated 
with AMPK and mTOR signaling were analysed 6 and 24 hours after treatment 
(DMSO, A-769662, erlotinib, and combination) of H1299 cells. ß-Actin was used as 
loading control. 
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Figure 5: Combinatorial treatment of H1299 xenograft with A-769662 and 
erlotinib strongly decreased tumor growth. (A) H1299 xenograft mice were 
treated for 5 days (day 7-11). Subcutaneous tumor growth (each treatment group 
with five replicates) was measured in-vivo during 34 days, and finally surgically 
removed. Student’s t-test showed significant reduction of tumor growth in 
combinatorial treated mice (*p= 0.03) versus single drug and control group (B) 
Resected tumors (three replicates closest to median size) from different treatment 
regimens were illustrated for growth response. 
 
